The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Mezigdomide + carfilzomib + dexamethasone regimen reduces disease progression in r/r MM, phase III trial finds

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Mezigdomide, carfilzomib, and dexamethasone demonstrated a >50% reduction in the risk of disease progression or death in patients with relapsed or refractory multiple myeloma compared to carfilzomib and dexamethasone, according to the results of the SUCCESSOR-2 phase III trial. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Talvey + Darzalez Faspro shows significant survival gains in r/r MM, phase III MonumenTAL-3 study finds

Talvey (talquetamab-tgvs), a GPRC5D bispecific antibody, in combination with Darzalez Faspro (daratumumab and hyaluronidase-fihj) with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72% and clinically meaningful reduction of up to 53% in the risk of death compared to the standard regimen of Darzalez Faspro, pomalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma, according to the results of the investigational phase III MonumenTAL-3 study. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account